Abstract: The invention relates to the use of calcium nitrate to reduce the pore size distribution of a hardened cementitious composition, preferably, a hardened concrete composition, wherein the cementitious (concrete) composition comprises between 1 weight % to 4 weight % of calcium nitrate of the cement content of the cementitious composition, depending on the type of cement. This results in a reduced permeability for the set cementitious (concrete) composition for carbon dioxide (CO2) and thus an elevated resistance towards carbonation. The invention furthermore relates to a method for producing such a hardened cementitious (concrete) composition and a pourable and curable (wet) concrete composition. The invention also relates to a steel reinforced concrete solid having an elevated resistance towards carbonation and a method for producing a steel reinforced concrete solid having an elevated resistance towards carbonation.

Abstract: A hardening accelerator for mineral binder compositions, in particular for cementitious binder compositions, including at least one phosphoric acid ester of a polyvalent alcohol and at least one alkali metal carbonate.

Abstract: A ceramic and plastic composite and a method for fabricating the same are disclosed. A chemical cleaning treatment, a microetching treatment, a hole reaming treatment, and a surface activating treatment are performed on the surface of a ceramic matrix to form nanoholes with an average diameter ranging between 150 nm and 450 nm. Plastics are injected onto the surface of the baked ceramic matrix to form a plastic layer. The plastic layer more deeply fills the nanoholes to have higher adhesion. Thus, the higher combined strength and air tightness exist between the ceramic matrix and the plastic layer to improve the reliability and the using performance of the ceramic and plastic composite.

Abstract: A system and method for separating nutrients, such as phosphorus and protein, from biological materials may be disclosed. Biological material, for example in the form of wet solids from raw manure, may first be separated out by a solid-liquid separator. The wet solids may then be dissolved in an acidic solution. The resulting supernatant from the acidic treatment may then be separated and phosphorus reclaimed therefrom. The resulting precipitate from the acidic treatment may be separated from the supernatant and treated with a basic solution. The resulting supernatant following the basic treatment may then be separated and protein reclaimed therefrom. In some embodiments, the supernatant resulting from the acidic treatment may itself be alkalinized, creating a precipitate which contains phosphorus solids and a supernatant which can be separated from the phosphorus solids and used as the basic solution with which to treat the precipitate resulting from the acidic treatment.

Abstract: A method is provided for producing a biochar solution. The method comprises the steps of collecting biochar particles, dispersing the biochar particles in a liquid solution and adding a stabilizing agent to keep the biochar in flowable suspension. The stabilizing agent may be added to the liquid solution or to the biochar prior to placing the biochar in solution.

Abstract: The present invention provides for the use of at least one oil soluble polymer comprising linear polymethylene sequences with an average of 10 to 40 consecutive methylene groups to improve the water resistance of an explosive composition comprising particulate ammonium nitrate and a fuel oil, said linear polymethylene sequences with in average 10 to 40 consecutive methylene groups may be either in the main chain or in the side chains of the oil soluble polymer.

Abstract: A pyrotechnic composition includes a fuel, an oxidizer, flow and rate control agents and oleoresin capsicum as an irritant. The composition is useful in crowd control products. The composition contains rate control ingredients to maintain combustion at a temperature below the point of degradation of the oleoresin capsicum, balanced with a booster material to maintain combustion.

Abstract: A method for preparing aromatic hydrocarbons with carbon dioxide hydrogenation, comprising: directly converting a mixed gas consisting of carbon dioxide and hydrogen with the catalysis of a composite catalyst under reaction conditions of a temperature of 250-450° C., a pressure of 0.01-10.0 MPa, a feedstock gas hourly space velocity of 500-50000 mL/(h·gcat) and a H2/CO2 molar ratio of 0.5-8.0, to produce aromatic hydrocarbons. The composite catalyst is a mixture of a first component and a second component. The first component is an iron-based catalyst for making low-carbon olefin via carbon dioxide hydrogenation, and the second component is at least one of metal modified or non-modified molecular sieves which are mainly used for olefin aromatization.

Abstract: Provided is a method for producing 1,3-butadiene that enables 1,3-butadiene to be obtained in a high yield while preventing abnormal reaction of a fraction containing vinylacetylene in high concentration. The method for producing 1,3-butadiene is a method for producing 1,3-butadiene from a fraction produced in separation and recovery of 1,3-butadiene from a C4 hydrocarbon mixture that includes: adding a diluent to a high VA fraction containing vinylacetylene to produce a diluted fraction; and subjecting the diluted fraction to hydrogenation treatment to produce 1,3-butadiene. Substantially only a low VA fraction is used as the diluent. The low VA fraction is a fraction that is produced in separation and recovery of 1,3-butadiene from the C4 hydrocarbon mixture and has a lower vinylacetylene concentration than the high VA fraction.

Abstract: This invention solves the problem of providing an efficient, new method for producing a fluoromethylene-containing compound. The problem can be solved by a method for producing a compound represented by formula (1) or a ring-closed or ring-opened derivative of the compound, wherein R1 represents an organic group, RX represents hydrogen or fluorine, R2a, R2b, R2c, and R2d are the same or different, and each represents —Y—R21 or —N(—R22)2, or R2b and R2c may join together to form a bond, wherein Y represents a bond, oxygen, or sulfur, R21 represents hydrogen or an organic group, and R22, in each occurrence, is the same or different and represents hydrogen or an organic group; the method comprising step A of reacting a compound represented by formula (2), wherein X represents a leaving group, and other symbols are as defined above, with a compound represented by formula (3), wherein the symbols are as defined above, in the presence of a reducing agent under light irradiation.

Abstract: The present invention relates to a process for preparing terpinene-4-ol from limonene-4-ol via a hydrogenation reaction in the presence of a nickel catalyst.

Abstract: A method for forming poly(dimethoxymethane) includes a step of separating a formaldehyde-containing blend into a first bottom stream and a first top stream. The first formaldehyde-containing blend includes methanol, formaldehyde, and water while the first bottom stream includes water. The first top stream includes dimethoxymethane that is produced from the reaction between methanol and formaldehyde. The first top stream is separated into a second bottom stream and a second top stream. The second bottom stream includes poly(dimethoxymethane) while the second top stream includes dimethoxymethane, methanol, and ethanol. The second top stream is separated into a third bottom stream and a third top stream. Third bottom stream includes methanol and ethanol while the third top stream includes dimethoxymethane. The third top steam can be recycled to form additional poly(dimethoxymethane). A system that implements the method is also provided.

Abstract: The present invention relates to polyethylene glycol derivatives and use thereof.

Abstract: Provided herein are naphthoquinones compounds such as those with a hydrogen bond donating group of the formula (I): wherein: R1, R2, R3, R4, R5, and n are as defined herein. Also provided herein are pharmaceutical composition of the present compounds and methods of treatment using the compounds including their use in the treatment of cancer.

Abstract: This disclosure provides for routes of synthesis of acrylic acid and other ?,?-unsaturated carboxylic acids and their salts, including catalytic methods. For example, there is provided a process for producing an ?,?-unsaturated carboxylic acid or a salt thereof, the process comprising: (1) contacting in any order, a group 8-11 transition metal precursor, an olefin, carbon dioxide, a diluent, and a polyaromatic resin with associated metal cations to provide a reaction mixture; and (2) applying conditions to the reaction mixture suitable to produce the ?,?-unsaturated carboxylic acid or a salt thereof. Methods of regenerating the polyaromatic resin with associated metal cations are described.

Abstract: A process for the recovery of polymer-grade (meth)acrylic acid, in the absence of organic solvent, from a gaseous reaction mixture comprising (meth)acrylic acid obtained by gas-phase oxidation of a precursor of the (meth)acrylic acid, the process carried out in a plant comprising at least one dehydration column and one finishing column, being characterized by the presence of at least one chemical treatment agent targeted at reducing the content of residual aldehydes. (Meth)acrylic acid obtained according to the invention meets criteria of high quality allowing it to be used in the manufacture of acrylic polymers, in particular for superabsorbents. This grade is also known as glacial acrylic acid GAA.

Abstract: The present invention relates to a method for continuous recovery of (meth)acrylic acid and an apparatus used for the recovery method. The recovery method according to the present invention enables stable recovery of (meth)acrylic acid and the operation of a continuous process, while securing a high (meth)acrylic acid recovery rate through the acetic acid separation process.

Abstract: The subject of the present invention is a process for the synthesis of C1-C10 alkyl (meth)acrylates, by direct esterification of the (meth)acrylic acid by the corresponding alcohol, the reaction being carried out in a fixed bed membrane reactor under conditions in which the water generated by the reaction is eliminated from the reaction mixture as it is formed. The process according to the invention may operate under conditions for which the reagents are not in excess, thereby minimizing the size and energy of the equipment for separation/recycling of the streams generated during the purification of the reaction medium.

Abstract: A high-yield process for preparing (4Z,7Z)-4,7-decadien-1-yl acetate, with reduced number of steps, without using a protecting group. A process for preparing (4Z,7Z)-4,7-decadien-1-yl acetate is provided, the process including at least the following steps: reducing a 10-halo-3,6-decadiyne of the general formula (1) to form a (3Z,6Z)-10-halo-3,6-decadiene of the general formula (2); and converting the (3Z,6Z)-10-halo-3,6-decadiene into (4Z,7Z)-4,7-decadien-1-yl acetate of the formula (4) having an acetoxy group in place of the halogen atom of the (3Z,6Z)-10-halo-3,6-decadiene.

Abstract: The invention is in the field of resveratrol derivative compounds and compositions, and methods for synthesizing same.

Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like HIV and AIDS, or the development of neoplasms in a mammalian subject. The methods and compositions of the invention are effective for inhibiting de novo HIV infection, upregulating viral expression from latent provirus, inhibiting HIV-induced cytopathic effects, down regulating the HIV receptor, increasing Th1 cytokine expression, decreasing Th2 cytokine expression, increasing ERK phosphorylation, inducing apoptosis in malignant cells, inducing remission, maintaining remission, as chemotherapeutic agents, as well as for decreasing symptoms of cytopathic diseases and opportunistic infections that may accompany such diseases.

Abstract: Process(es) produce compositions comprising dimethyl terephthalate (DMTA) for polymer chains having terephthalate moieties containing carbons from ethanol having at least two of the carbon atoms in the terephthalate ring that are fossil based. The compounds produced by the process(es) are DMTA polymers. The Henkel process converts ethanol to ethylene oxide, beta propiolactone, and/or terephthalic acid which can all serve as substituents producing DMTA by the process(es) disclosed. A production of DMTA by the process(es) disclosed herein result in DMTA with two ethanol-derived carbon atoms in the terephthalate ring with the carboxy group. In the production of terephthalate derived by process(es) disclosed herein by reaction of ethylene with dimethylfuran bond both of the ethylene-derived carbons to unsubstituted positions of the aromatic ring.

Abstract: The present invention concerns a process for forming a primary or a secondary amine via amination reaction comprising: reacting an alcohol with an amine in the presence of a zeolite comprising a transition metal chosen in the group consisting of Group 8 to 12 elements of the Periodic Table and any combination thereof.

Abstract: The present invention relates to a modification monomer and a modified conjugated diene-based polymer including the same, and more particularly, provides a modification monomer represented by Formula 1 and a modified conjugated diene-based polymer including a repeating unit derived therefrom.

Abstract: The present application provides a preparation method of a formamide compound, the preparation process includes: uniformly mixing raw material of methanoic acid and an amine compound selected from a primary amine or a secondary amine to prepare a homogeneous reaction system; the above homogeneous reaction system is heated to 160-230° C., allowing carbon monoxide to be decomposed from the homogeneous reaction system and participates in the reaction, and collecting the reaction product to obtain a formamide compound. The present application provides a new technology using a homogeneous method to synthesize a formamide compound, the reaction process needs no use of a catalyst, the operation process is simple and controllable, and the raw material of the amine compound has a high selectivity.

Abstract: The present invention discloses a process for the preparation of Iopamidol of formula (II) and comprising the following steps: a) reacting the Compound (I) wherein X is OR2 or R3, and wherein R2 and R3 are a Ci-C6 linear or branched alkyl, C3-C6 cycloalkyl, C6 aryl, optionally substituted with a group selected from the group consisting of methyl, ethyl, n-propyl, i-propyl, n-butyl, sec-butyl, t-butyl and phenyl, with the acylating agent (S)-2-(acetyloxy)propanoyl chloride in a reaction medium to provide the acetyloxy derivative of Compound (I); b) hydrolyzing the intermediate from step a) with an aqueous solution at a pH comprised from 0 to 7, by adding water or a diluted alkaline solution such as sodium hydroxide or potassium hydroxide, freeing the hydroxyls from the boron-containing protective groups, obtaining the N—(S)-2-(acetyloxy)propanoyl derivative of Compound (II); c) alkaline N hydrolysis to restore the (S)-2-(hydroxy)propanoyl group and to obtain Iopamidol (II) and optional recovery of the boron de

Abstract: An octahydroanthracene compound having the structure shown in formula (I) and (II), preparation method and application thereof are disclosed. The octahydroanthracene compound has a good therapeutic effect on tumors and neurodegenerative diseases. The preparation of the octahydroanthracene compound is mainly carried out by using benzene as a starting material, and being subjected to Friedel-Crafts reaction, nitration, reduction, (sulfo-) amide formation, reduction, urea formation or amide formation, thus obtaining a target compound.

Abstract: The present invention relates to a process for the preparation of an alkanesulfonic acid by oxidation of a sulfur containing starting compound with an oxygen containing fluid, wherein the sulfur containing starting compound is provided in a reaction system, comprising a reaction vessel (1) with an expansion vessel (2) on its top, wherein the reaction vessel and the expansion vessel are connected to allow a flow of a fluid stream from the reaction vessel into the expansion vessel.

Abstract: The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, having same as an active ingredient. The inventors identified a novel compound containing BTL2 inhibitory activity, and experimentally confirmed that the present novel compound had an excellent effect on the enhancement of the cancer cell death, on the inhibition of the metastasis and chemotactic mobility, and on the anti-asthma activity. Therefore, the present novel compound can be used as a very effective pharmaceutical component for treating the inflammatory-related diseases.

Abstract: The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.

Abstract: Aqueous emulsion comprising: —25-70 wt % organic peroxide, based on the weight of the emulsion, —a cyclohexane dicarboxylate ester, and —water. This emulsion is storage stable and can be used for the production of polymers, in particular PVC, that come into contact with food products.

Abstract: [Problem] To provide a compound useful as a cathepsin S inhibitor. [Means for Solution] The present inventors have examined a compound that has a cathepsin S inhibitory effect and is usable as an active ingredient of a pharmaceutical composition for preventing and/or treating autoimmune disease including systemic lupus erythematosus (SLE) and lupus nephritis, allergies, or graft rejection of an organ, bone marrow or tissue, and have found that a phenyldifluoromethyl-substituted prolinamide compound of the present invention has the cathepsin S inhibitory effect, thereby completing the present invention. The phenyldifluoromethyl-substituted prolinamide compound of the present invention has the cathepsin S inhibitory effect and is useful as an agent for preventing and/or treating autoimmune disease including SLE and nephritis, allergies, or graft rejection of an organ, bone marrow or tissue.

Abstract: The present invention relates inter alia to a compound of formula (I) wherein R1, R2 and R3, are as defined in the specification and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in treatment, for example in the treatment of fibrotic diseases or interstitial lung diseases, in particular idiopathic pulmonary fibrosis.

Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.

Abstract: The present invention relates to an improved process for the preparation of Apremilast of formula (I).

Abstract: The present application provides solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide, and methods of preparing and using same.

Abstract: The present invention provides a compound represented by formula (I) (in the formula, R1 to R4 each represent a hydrogen atom, an unsubstituted or G1-substituted C1-6 alkyl group or the like, A represents an oxygen atom or the like, Cy represents a C6-10 aryl group or the like), an N-oxide compound thereof, a tautomer or salt thereof. The present invention also provides an agricultural and horticultural fungicide, harmful organism control agent and insecticidal/acaricidal agent containing at least one compound selected from the group consisting of a compound represented by formula (I), a tautomer and salt thereof, as an active ingredient.

Abstract: Compounds of Formula (I): and salts thereof, and methods of use as Janus kinase inhibitors are described herein.

Abstract: Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders.

Abstract: A method for producing an isocyanuric acid derivative having two hydrocarbon groups including: a first step of obtaining a compound of Formula (1); a second step of obtaining a compound of Formula (2) from the compound of Formula (1); a third step of obtaining a compound of Formula (3) from the compound of Formula (2); and a fourth step of obtaining a compound of Formula (4) from the compound of Formula (3), wherein Bn is a benzyl group, and two Rs are each a C1-10 hydrocarbon group, wherein all the steps are carried out at a temperature not exceeding 100° C.

Abstract: The present invention relates to compounds formula (I): wherein P is P1, P2, heterocyclyl or heterocyclyl substituted by one to five Z; and wherein A1, A2, A3, A4, G1, R1, R2, R3, R4, R5, R6, R17, R18, R19 and R20 are as defined herein; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to insecticidal, acaricidal, nematicidal and molluscicidal compositions comprising the compounds of formula (I) and to methods of using the compounds of formula (I) to control insect, acarine, nematode and mollusc pests.

Abstract: The present invention relates to a compound of formula III, wherein, R is selected from the group consisting of C1-C4 alkyl, substituted or unsubstituted phenyl, and substituted or unsubstituted benzyl, preferably isopropyl; and two Ar groups may be the same or different, and are each independently selected from the group consisting of substituted or unsubstituted aryl groups, preferably substituted or unsubstituted phenyl, such as p-methoxyphenyl and the like, wherein the compound is preferably in a solid form.

Abstract: The present invention discloses a monoepoxy compound represented by the following Formula (1), a curable composition containing the same, a cured product therefrom, a method of producing the monoepoxy compound, and a reactive diluent containing the monoepoxy compound. The monoepoxy compound represented by the Formula (1) is useful in that it is capable of reducing the viscosity of a curable composition containing the monoepoxy compound, while preventing a reduction in the heat resistance of the curable composition as well as a reduction in the weight of the curable composition upon curing. (In the Formula (1), R1 to R6 are each independently selected from the group consisting of a hydrogen atom, an alkyl group, and an alkoxy group.

Abstract: Provided herein are 3-phenyl-7-hydroxy-isocoumarin compounds which are MIF inhibitors; compositions comprising said inhibitors and methods for treating or preventing diseases associated with MIF.

Abstract: Provided is a novel aromatic amine derivative represented by General Formula (G1) below. (In the formula, A represents oxygen or sulfur, and R1 to R7 individually represent any of a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a substituted or unsubstituted phenyl group, and a substituted or unsubstituted biphenyl group. In addition, ?1 and ?2 individually represent a substituted or unsubstituted phenylene group. Further, Ar1 represents a substituted or unsubstituted condensed aromatic hydrocarbon having 14 to 18 carbon atoms included in a ring. Further, Ar2 represents a substituted or unsubstituted aryl group having 6 to 13 carbon atoms included in a ring. Further, j and n are individually 0 or 1, and p is 1 or 2.

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Abstract: The present invention provides a compound of Formula I wherein Q is selected from the group consisting of —CH(CH3)2 and R is selected from the group consisting of or a pharmaceutically acceptable salt thereof; compositions, methods to treat liver disease and NASH.

Abstract: Provided herein is a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate. Pharmaceutical compositions comprising the crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate are also disclosed.

Abstract: The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders. The present application also provides methods for making compounds of the application and intermediates thereof.

Abstract: Compounds For Inhibition Of Cancer and Epigenesis. The present invention relates to quinolines and 5,6,7,8-tetrahydroacridines of the formula (I) wherein Z1, Z2, X, R1 to R8 and Y are defined as described in the specification, or a pharmaceutically acceptable form or prodrug thereof, that are inhibitors of methyl transferases such as protein lysine methyltransferases and more particularly SMYD3. The present invention also relates to the methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of disorders/conditions/diseases involving, relating to or associated with enzymes having methyl transferase activities/functions and/or via unspecified/multi-targeted mechanisms.